Generic Orilissa Availability

Last updated on Jul 9, 2025.

Orilissa is a brand name of elagolix, approved by the FDA in the following formulation(s):

ORILISSA (elagolix sodium - tablet;oral)

• Manufacturer: ABBVIE
  Approval date: July 23, 2018
  Strength(s): EQ 150MG BASE ^[RLD], EQ 200MG BASE ^[RLD]

Is there a generic version of Orilissa available?

No. There is currently no therapeutically equivalent version of Orilissa available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Orilissa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Methods of administering elagolix
  Patent 10,537,572
  Issued: January 21, 2020
  Inventor(s): Goss Sandra L. & Klein Cheri E. & Ng Juki Wing-Keung & Salem Ahmed
  Assignee(s): AbbVie Inc.
  

  The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.

  Patent expiration dates:

  • September 1, 2036
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150MG ELAGOLIX WHILE CO-ADMINISTERING RIFAMPIN
• Methods of administering elagolix
  Patent 10,682,351
  Issued: June 16, 2020
  Inventor(s): Goss Sandra L. & Klein Cheri E. & Ng Juki Wing-Keung & Salem Ahmed
  Assignee(s): ABBVIE INC.
  

  The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.

  Patent expiration dates:

  • September 1, 2036
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG ELAGOLIX WHILE CO-ADMINISTERING KETOCONAZOLE
• Methods of treating heavy menstrual bleeding
  Patent 11,344,551
  Issued: May 31, 2022
  Inventor(s): Chwalisz; Kristof et al.
  Assignee(s): AbbVie Inc. (North Chicago, IL)
  

  The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Patent use: USE OF ELAGOLIX 200 MG BID FOR 6 MONTHS TO MANAGE MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN PREMENOPAUSAL WOMEN TO REDUCE DYSMENORRHEA AND NON-MENSTRUAL PELVIC PAIN
  • March 14, 2034
    
    ✓ 
    Patent use: USE OF ELAGOLIX 200 MG BID FOR 6 MONTHS TO MANAGE MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN PREMENOPAUSAL WOMEN HAVING DYSPAREUNIA ASSOCIATED WITH ENDOMETRIOSIS
• Elagolix sodium compositions and processes
  Patent 11,542,239
  Issued: January 3, 2023
  Inventor(s): Chauhan; Niharika et al.
  Assignee(s): AbbVie Inc. (North Chicago, IL)
  

  The present invention relates to compositions of elagolix sodium, and process and intermediates for the preparation thereof.

  Patent expiration dates:

  • July 23, 2039
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Methods of administering elagolix
  Patent 11,690,845
  Issued: July 4, 2023
  Inventor(s): Ali; Farah N. et al.
  Assignee(s): AbbVie Inc. (North Chicago, IL)
  

  The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, where the methods involve administration of elagolix and may further involve co-administration of a CYP2B6 substrate (e.g., bupropion) or a CYP2C19 substrate (e.g., omeprazole).

  Patent expiration dates:

  • August 27, 2040
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG OR 200 MG ELAGOLIX WHILE CO-ADMINISTERING OMEPRAZOLE
• Methods of treating heavy menstrual bleeding
  Patent 11,690,854
  Issued: July 4, 2023
  Inventor(s): Ng; Juki Wing-Keung et al.
  Assignee(s): AbbVie Inc. (North Chicago, IL)
  

  The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

  Patent expiration dates:

  • April 19, 2038
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN A PATIENT WITH MODERATE HEPATIC IMPAIRMENT
• Methods of treating heavy menstrual bleeding
  Patent 11,707,464
  Issued: July 25, 2023
  Inventor(s): Chwalisz; Kristof et al.
  Assignee(s): AbbVie Inc. (North Chicago, IL)
  

  The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG ELAGOLIX FOR UP TO 24 MONTHS
• Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
  Patent 12,102,637
  Issued: October 1, 2024
  Inventor(s): Jayanth; Jayanthy et al.
  Assignee(s): AbbVie Inc. (North Chicago, IL); Neurocrine Biosciences, Inc. (San Diego, CA)
  

  The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

  Patent expiration dates:

  • August 20, 2038
    
    ✓ 
    Drug product
• Gonadotropin-releasing hormone receptor antagonists and methods related thereto
  Patent 7,419,983
  Issued: September 2, 2008
  Inventor(s): Guo; Zhiqiang et al.
  Assignee(s): Neurocrine Biosciences, Inc. (San Diego, CA)
  

  GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: ##STR00001## wherein R.sub.1a, R.sub.1b, R.sub.1c, R.sub.2a, R.sub.2b, R.sub.3, R.sub.4, R.sub.5, R.sub.6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

  Patent expiration dates:

  • July 6, 2029
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS
    ✓ 
    Drug substance
    ✓ 
    Drug product

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer